title: Multidisciplinary management of small cell lung cancer.
abstract: The standard treatment of limited-stage small cell lung cancer (SCLC) is concurrent cisplatin and etoposide with thoracic radiation therapy, whereas treatment of extensive-stage disease is typically chemotherapy alone with a platinum compound plus etoposide. Surgical resection of early disease is generally reserved for patients with small, node-negative disease. Prophylactic cranial irradiation reduces the development of brain metastases and prolongs survival in patients with both limited-stage and extensive-stage disease who have responded to chemotherapy. Further understanding of the molecular underpinnings of SCLC is necessary to develop better treatment options and improve outcomes for patients.
authors: Department of Hematology/Oncology, Yale Cancer Center, New Haven, CT 06520, USA.
authors: Sarah B
authors: SB
authors: Goldberg
authors: Henning
authors: H
authors: Willers
authors: Rebecca S
authors: RS
authors: Heist
mesh_terms: D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D055752:Small Cell Lung Carcinoma / Q000628:therapy*